In the Era of Neoadjuvant Chemo-Immunotherapy for Resectable Locally Advanced Stage III NSCLC, Neoadjuvant Chemoradiotherapy Is No Longer a Standard of Care
Year: 2026
Type: editorial
Source: Journal of Thoracic Oncology
Institutions: University of Zurich, University Hospital Zurich
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7208728510
